title: [Current status of new drug development for inflammatory bowel diseases].
authors.affiliation: Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University.
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Kohgo
authors.forename: Hiroki
authors.initials: H
authors.lastname: Tanabe
authors.forename: Mikihiro
authors.initials: M
authors.lastname: Fujiya
mesh_terms: D000068879:Adalimumab; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000068582:Certolizumab Pegol; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D000069285:Infliximab; D019804:Mesalamine / Q000627:therapeutic use; D000069442:Natalizumab; D011092:Polyethylene Glycols / Q000627:therapeutic use; D013256:Steroids / Q000627:therapeutic use; D000069549:Ustekinumab
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007140:Immunoglobulin Fab Fragments; D000069442:Natalizumab; D013256:Steroids; D011092:Polyethylene Glycols; D019804:Mesalamine; C529000:golimumab; C543529:vedolizumab; D000069285:Infliximab; D000069549:Ustekinumab; D000068879:Adalimumab; C502936:tocilizumab; D000068582:Certolizumab Pegol